期刊
OPHTHALMOLOGICA
卷 230, 期 3, 页码 109-115出版社
KARGER
DOI: 10.1159/000351426
关键词
Rituximab; Uveitis; Intra-ocular inflammation; CD20; Birdshot chorioretinopathy; Remission
资金
- Department of Health [CDF-2011-04-051] Funding Source: Medline
- Academy of Medical Sciences (AMS) [AMS-SGCL4-Taylor] Funding Source: researchfish
- National Institute for Health Research [CDF-2011-04-051] Funding Source: researchfish
Treatment of non-infectious uveitis is based primarily on the use of systemic corticosteroids and second-line immunosuppressive drugs. However, their extensive side effect profile, particularly for steroids, has led to the increased use of other immunosuppressive drugs, as sparing capacity agents. Rituximab is an anti-CD20 chimeric antibody, often given as a single course of 2 infusions, resulting in complete depletion of peripheral mature B cells. While it is licensed to treat refractory systemic lymphoma patients, it has also shown promising results in systemic auto-immune diseases, where a single course of treatment is able to achieve long-term clinical remission. Treatment with rituximab has been reported for various ocular conditions, suggesting it may be effective in inducing long-term disease control and other systemic immunosuppressive agents can be reduced or discontinued. When disease relapse occurs, a further course or courses can be given with good results. This review summarizes the current evidence regarding the role of rituximab in treating non-infectious uveitis. (C) 2013 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据